Hypertriglyceridemia-why, when and how should it be treated?

Area of Science:

• Cardiology
• Endocrinology
• Metabolic Syndrome

Background:

• The link between serum triglyceride levels and cardiovascular disease (CVD) remains unclear despite extensive research.
• Hypertriglyceridemia is often considered an independent risk factor for CVD, yet no specific triglyceride targets exist for prevention.
• Current lipid-lowering therapies prioritize optimizing low-density lipoprotein (LDL) cholesterol for overall cardiovascular risk reduction.

Purpose of the Study:

• To review the existing evidence on the relationship between triglyceride levels and cardiovascular disease.
• To discuss therapeutic strategies for managing hypertriglyceridemia.
• To highlight the need for prospective trials investigating the clinical impact of triglyceride reduction on cardiovascular outcomes.

Main Methods:

• Review of existing epidemiological data and clinical trial analyses.
• Analysis of post-hoc data from studies like the Helsinki Heart Study, VA-HDL, and BIPS.
• Synthesis of evidence regarding lifestyle modifications and pharmacological interventions (fibrates, omega-3 fatty acids, niacin).

Main Results:

• Evidence suggests hypertriglyceridemia may be an independent CVD risk factor.
• Post-hoc analyses indicate potential benefits of fibrates in treating hypertriglyceridemia, particularly in obese, insulin-resistant individuals.
• Current guidelines focus on LDL cholesterol reduction, not specific triglyceride targets.

Conclusions:

• While evidence suggests a link, the precise role of triglycerides in CVD requires further investigation.
• Therapeutic options for triglyceride lowering include lifestyle changes and medications like fibrates.
• Prospective trials are essential to determine if reducing triglyceride levels directly impacts clinical endpoints such as coronary events and stroke.